ORPH Live signaler | Maksimer profitt med Getagraph.com

Live Chart Being Loaded With Signals

Commentary (1 jan 1970 @ 01:00):

Stats
Dagens volum	941 412
Gjennomsnittsvolum	1.38M
Markedsverdi	0.00
EPS	$0 ( 2022-04-05 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.227
ATR14	$0.157 (18.05%)

Insider Trading

Date	Person	Action	Amount	type
2005-04-18	Orbimed Advisors Llc	Buy	0	Not reporting securities information.
2004-06-30	Stahl Pamela J	Buy	17 500	Stock Option (Right to Buy)
2004-06-15	Champsi Farah	Buy	5 000	Non-employee Director Stock Options (Right to Buy)
2004-06-15	Vida Julius A	Buy	5 000	Non-employee Director Stock Option (Right to Buy)

INSIDER POWER
0.00
Last 3 transactions
Buy: 27 500 \| Sell: 0

Volum Korrelasjon

Lang: -0.13 (neutral)

Kort: 0.26 (neutral)

Signal:(38.295) Neutral

Orphazyme A/S Korrelasjon

10 Mest positive korrelasjoner

10 Mest negative korrelasjoner

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Orphazyme A/S Korrelasjon - Valuta/Råvare

0.80
( moderate )

0.87
( strong )

0.00
( neutral )

0.90
( strong )

-0.05
( neutral )

-0.79
( moderate negative )

Orphazyme A/S Økonomi

Annual	2020
Omsetning:	$0.00
Bruttogevinst:	$0.00 (0.00 %)
EPS:	$-22.32

FY	2020
Omsetning:	$0.00
Bruttogevinst:	$0.00 (0.00 %)
EPS:	$-22.32

FY	2019
Omsetning:	$0.00
Bruttogevinst:	$0.00 (0.00 %)
EPS:	$-16.87

FY	2018
Omsetning:	$0.00
Bruttogevinst:	$0.00 (0.00 %)
EPS:	$-11.50

Financial Reports:

No articles found.

Orphazyme A/S

Orphazyme A/S, a biopharmaceutical company, develops therapies for the treatment of neurodegenerative orphan diseases. The company focuses on the amplification of heat-shock proteins to develop and commercialize therapeutics for diseases caused by protein misfolding and aggregation, and lysosomal dysfunction, including lysosomal storage and neuromuscular degenerative diseases. Its lead candidate is the Arimoclomol, which is in clinical development for four orphan diseases, including Niemann-Pick disease type C, Amyotrophic Lateral Sclerosis, Inclusion Body Myositis, and Gaucher disease. The company was incorporated in 2009 and is headquartered in Copenhagen, Denmark.